Autolus Therapeutics plc 8K

Autolus Therapeutics reported strong Q2 2026 revenue growth and margin expansion from AUCATZYL, raised 2026 revenue guidance, and bolstered liquidity with a new $250 million credit facility while advancing its clinical pipeline and implementing cost-saving measures.

Autolus Therapeutics plc reported strong second quarter 2026 results highlighted by a 119% year-over-year increase in AUCATZYL (obe-cel) net product revenue to $45.7 million, materially improved gross margin to 55% driven by higher volumes and cost reductions, and a raised full-year 2026 AUCATZYL revenue outlook to $140–$150 million, while also strengthening its capital structure through a new five-year, interest-only senior credit facility of up to $250 million with Perceptive Advisors (including $75 million funded at closing and additional tranches tied to milestones). The company confirmed progress across its pipeline, including ongoing trials for obe-cel in pediatric r/r B-ALL, lupus nephritis, systemic lupus erythematosus, and progressive multiple sclerosis, as well as AUTO8 in light-chain amyloidosis, and reiterated that a previously announced 13% workforce reduction and cost-efficiency initiative is substantially complete and expected to deliver approximately $15 million in annualized savings starting in 2027, supporting projected liquidity to fund operations into the second quarter of 2028.

Filing Facts

CIK

1730463

Ticker

AUTL

Form

8K

Source Type

fda

Accession

0001730463-26-000119

Alert Tier

7